Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | ABBV-101 |
| Indication/Tumor Type | diffuse large B-cell lymphoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | diffuse large B-cell lymphoma | predicted - sensitive | ABBV-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ABBV-101 treatment resulted in tumor regression in a cell line xenograft model of diffuse large B-cell lymphoma harboring BTK C481S (Cancer Res (2024) 84 (6_Supplement): 605). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract 605: ABBV-101, a highly potent and selective clinical stage Bruton tyrosine kinase degrader, overcomes BTK mutation-induced resistance to BTK inhibitors | Full reference... |